MyoLoop for cardiovascular research

Reference number 10482

Sectors: Biotechnology, Medical research

Industries: Cardiovascular

MyoLoop is a device that simulates the synchronised mechanical and electrical events that occur in the heart inside the body (in vivo), on an in vitro heart model known as myocardial slice (MS). The system is self-contained, and designed for chronic experiments, that is culture of myocardial slices. MyoLoop can simulate pathological conditions (e.g. hypertension), to study their progression, and the effects of therapeutic interventions on them.

Proposed use

  • Preclinical drug testing
  • Modelling cardiac diseases in vitro
  • Studying the effect of interventions on the heart in vitro
  • Engineered heart tissue maturation

Problem addressed

There are no devices that simulate the in vivo cardiac cycle at the in vitro level.

MyoLoop runs a custom software that simulates the cardiac cycle allowing myocardial slices (an in vitro cardiac model) to beat as they would in vivo.

A simple graphical user interface offers control of the cardiac cycle parameters, allowing researchers to study of a spectrum of physiological or pathological conditions.

MyoLoop is a standalone device. Using it is as simple as placing it on a lab bench.

Technology overview

MyoLoop is the first commercially available device that chronically cultures heart tissue, under the same mechanical and electrical events that occur inside the body, by recreating the cardiac cycle.

  • Simulation of cardiac cycle. Myocardial slices perform work loops as they would in vivo. The cardiac cycle parameters are user-selected and can be changed to simulate disease and health.
  • MyoLoop is a standalone benchtop device. It is easy to use and comes configured with:
    • Temperature control (i.e. no incubator is required)
    • Culture media recirculation (no peristaltic pump is required)
    • Tissue pacing (i.e. no external stimulator required)
    • Automatic data analysis software
    • Autoclavable culture chamber
    • Compact and sturdy design

Benefits

  • First device to recreate cardiac cycle in vitro for chronic culture experiments
  • Standalone device
  • For basic and translational research

Intellectual property information

The technology is protected by a provisional patent application.

Inventor

Professor Cesare Terracciano

Professor of Cardiac Electrophysiology
Faculty of Medicine, National Heart & Lung Institute

Visit personal site

Contact us about this technology



Contact

Dr Emily Allen-Benton

Industry Partnerships and Commercialisation Executive, Medicine

Emily is an IPC Executive within the Faculty of Medicine team focussed on intellectual property management, supporting Imperial academics with commercial engagement, fostering collaborative research and negotiating out-licenses. Emily manages an IP portfolio which included the Faculty of Medicine Quicktech portfolio, comprising mouse models and other research tools. Emily holds a PhD in Chemistry focussed on the sub-field of Synthetic Biology and has prior experience in the scientific publishing industry.

Contact Emily

[email protected]

Related technologies

Methods to scale production of hPSC-derived endothelial cells

Methods to scale production of hPSC-derived endothelial cells

A new 3D-culture methodology using stirred-tank bioreactors as a scalable platform for the production of hPSC-derived endothelial cells Find out more

MyoLoop for cardiovascular research

MyoLoop for cardiovascular research

MyoLoop is a device that can simulate pathological conditions (e.g. hypertension), to study their progression, and the effects of therapeutic interventions on them. Find out more

Two distinct late stage preclinical lead series of highly specific inhibitors of MAP4K4

Two distinct late stage preclinical lead series of highly specific inhibitors of MAP4K4

A late-stage, pre-clinically validated inhibitor of MAP4K4 for a range of indications including anthracycline cardiotoxicity Find out more

Sign up for updates

Sign up for monthly technology alerts via email, and find other ways to connect with us.

Loading...